Jeena Sikho
Health | Wealth | Happiness

Date: 14th November, 2026

To, Manager - Listing Compliance **National Stock Exchange of India Limited** 'Exchange Plaza'. C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 SYMBOL: JSLL	**To,** Head of the Department, Department of Listing Operation, **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400001 SCRIP Code: 544476

Subject: Outcome of the Meeting of the Board of Directors of Jeena Sikho Lifecare Limited held on November 14, 2026

Ref: Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of **Jeena Sikho Lifecare Limited ("the Company"),** at its meeting held today i.e. **Saturday, 14th November, 2026** at the registered office situated in SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab – 140604. has, inter alia, considered and approved the following matter:

1. **Approval of Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2026 along with Limited Review Report.**

The Board of Directors, on the recommendation of the Audit Committee, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026, together with the Limited Review Reports issued by the Statutory Auditors thereon, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforesaid Unaudited Standalone and Consolidated Financial Results, together with the respective Limited Review Reports, are enclosed herewith as **Annexure I.**

The meeting of the Board of Directors of the Company commenced at 4:45 p.m. IST and concluded at 06:05 p.m. IST

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road,
New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

The above intimation is also being made available on the Company's website at www.jeenasikho.com

You are requested to take the above information on record and disseminate the same on your website.

Thanking you,

Yours faithfully,
For Jeena Sikho Lifecare Limited

MANISH GROVER
Digitally signed by MANISH GROVER
Date: 2026.11.14 20:36:46 +05'30'

Manish Grover
Managing Director
DIN: 07557886

Date: 14.11.2026
Place: Zirakpur, Punjab

Registered Office Address:
SCO-11, Kalgidhar Enclave, Baltana, Zirakpur,
Punjab-140604, 01762-513185
CIN NO.: L52601PB2017PLC046545

Corporate Office Address:
B-26, Opp. Metro Pillar No. 223, Rohtak Road,
New Multan Nagar, Delhi - 110056
Email ID.: cs@jeenasikho.com | www.jeenasikho.com

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP

B-309, 3rd Floor,
Elante Office Building,
Industrial Area, Phase I,
Chandigarh - 160 002
India

T +91 172 403 8182

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jeena Sikho Lifecare Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jeena Sikho Lifecare Limited ('the Company') for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013



Sandeep Mehta
Partner
Membership No.: 099410
UDIN: 26099410ZZFPYP8386

Place: Chandigarh
Date: 14 November 2026

Walker Chandiok & Co LLP

Walker Chandiok & Co LLP

B-309, 3rd Floor,
Elante Office Building,
Industrial Area, Phase I,
Chandigarh - 160 002
India

T +91 172 403 8182


Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jeena Sikho Lifecare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jeena Sikho Lifecare Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial results of two subsidiaries included in the Statement, whose financial information reflects total assets of ₹1,334.07 lacs as at 30 September 2026, and total revenues of ₹ Nil and ₹ Nil, total net profit after tax of ₹29.03 lacs and ₹48.87 lacs, total comprehensive income of ₹29.17 lacs and ₹49.00 lacs for the quarter and year-to-date period ended on 30 September 2026, respectively, and net cash outflows of ₹ 0.30 lacs for the period ended 30 September 2026, as considered in the Statement. These interim financial results have been reviewed by other auditor whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the review reports of such other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013



Sandeep Mehta
Partner
Membership No. 099410
UDIN: 26099410QNAZYY9507

Place: Chandigarh
Date: 14 November 2026

Walker Chandiok & Co LLP

Annexure 1

List of entities included in the Statement

Subsidiaries:

1. Jeena Sikho International LLC
2. Jeena Green Resources Private Limited



JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91- 01762-513185

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

Standalone Balance sheet as at: (Amount in Rs. lacs)

Particulars	30 September 2026 (Unaudited)	31 March 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	9,291.43	11,700.61
Right-of-use assets	14,901.64	11,404.12
Capital work-in-progress	126.15	191.56
Goodwill	5,811.82	5,811.82
Other intangible assets	191.27	260.15
Intangible assets under development	105.02	79.45
Financial assets		
(i) Investments	2,185.58	1,487.54
(ii) Loans	1,090.09	1,045.66
(iii) Other financial assets	1,288.38	1,173.81
Deferred tax asset (Net)	1,412.86	1,025.51
Other non-current assets	241.91	98.73
Total Non-current assets (A)	**36,646.15**	**34,278.96**
Current assets		
Inventories	3,161.78	2,017.12
Financial assets		
(i) Investments	10,289.11	9,512.24
(ii) Trade receivables	7,380.54	6,992.91
(iii) Cash and cash equivalents	6,754.03	1,515.62
(iv) Other bank balances	10,616.04	9,245.08
(v) Loans	40.94	26.40
(vi) Other financial assets	4,527.13	2,269.20
Other current assets	3,253.36	1,453.99
Total Current assets (B)	**46,022.93**	**33,032.56**
TOTAL ASSETS (A+B)	**82,669.08**	**67,311.52**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	2,486.01	2,486.01
Other equity	49,221.96	44,254.04
Total Equity (C)	**51,707.97**	**46,740.05**
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	20.08	26.50
(ii) Lease liabilities	13,109.06	9,548.25
(iii) Others financial liabilities	74.38	80.85
Provisions	602.04	562.52
Other non-current liabilities	6.92	12.49
Total Non-current liabilities (D)	**13,812.48**	**10,230.61**
Current liabilities		
Financial liabilities		
(i) Borrowings	10.32	16.42
(ii) Lease liabilities	3,678.88	3,136.09
(iii) Trade payables		
(a) Total outstanding dues of micro and small enterprises	827.65	617.33
(b) Total outstanding dues of creditors other than micro and small enterprises	2,149.80	1,545.03
(iv) Other financial liabilities	8,006.73	2,488.46
Other current liabilities	2,013.52	1,645.01
Provisions	324.05	77.63
Current tax liabilities (net)	137.68	814.89
Total Current liabilities (E)	**17,148.63**	**10,340.86**
Total liabilities (F=D+E)	**30,961.11**	**20,571.47**
TOTAL EQUITY AND LIABILITIES (C+F)	**82,669.08**	**67,311.52**

This space has been intentionally left blank

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

JEENA SIKHO LIFECARE LIMITED ZIRAKPUR

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91 - 01762-513185

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026

(Amount in Rs. lacs)

S. No.	Particulars	Quarter ended			Six months ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income**						
	a. Revenue from operations	23,512.91	22,440.48	18,984.51	45,953.39	36,413.10	80,134.64
	b. Other income	(231.22)	1,401.51	144.49	1,170.29	251.34	865.89
	Total Income	**23,281.69**	**23,841.99**	**19,129.00**	**47,123.68**	**36,664.44**	**81,000.53**
2	**Expenses**						
	a. Purchase of stock-in-trade and ayurvedic healthcare consumables	3,796.80	2,703.05	2,558.84	6,499.85	4,646.31	10,011.39
	b. Changes in inventories of stock-in-trade and ayurvedic healthcare consumables	(1,003.05)	(136.20)	(150.00)	(1,139.25)	(404.00)	(862.53)
	c. Employee benefits expense	4,826.74	4,417.79	3,316.87	9,244.53	6,313.02	14,840.48
	d. Finance costs	404.12	347.19	434.60	751.31	600.58	1,283.35
	e. Depreciation and amortization expense	1,642.98	1,532.78	1,039.86	3,175.76	2,004.77	4,757.82
	f. Other expenses	8,689.98	6,243.81	4,052.68	14,933.79	8,772.58	21,182.55
	Total Expenses	**18,357.57**	**15,108.42**	**11,252.85**	**33,465.99**	**21,933.26**	**51,213.06**
3	**Profit before tax (1-2)**	**4,924.12**	**8,733.57**	**7,876.15**	**13,657.69**	**14,731.18**	**29,787.47**
4	**Tax expense / (credit)**						
	a. Current tax	1,717.81	2,137.61	2,052.33	3,855.42	3,830.46	8,017.00
	b. Taxation for earlier years	-	-	-	-	-	14.10
	c. Deferred tax	(427.40)	26.78	(54.76)	(400.62)	(109.00)	(461.20)
	Total tax expense	**1,290.41**	**2,164.39**	**1,997.57**	**3,454.80**	**3,721.46**	**7,569.90**
5	**Profit for the quarter/ period/ year (3-4)**	**3,633.71**	**6,569.18**	**5,878.58**	**10,202.89**	**11,009.72**	**22,217.57**
6	**Other comprehensive income**						
	(i) Items that will not be reclassified to profit or loss						
	- Remeasurement gain / (loss) on defined benefit plans	(10.32)	63.08	9.19	52.76	68.21	79.01
	- Income tax related to items that will not be reclassified to profit or loss	2.59	(15.87)	(2.32)	(13.28)	(17.17)	(19.88)
7	**Total comprehensive income for the quarter/ period/ year (5+6)**	**3,625.98**	**6,616.39**	**5,885.45**	**10,242.37**	**11,060.76**	**22,276.70**
8	**Paid-up equity share capital (Face value of Rs. 2 each)**	2,486.01	2,486.01	2,486.01	2,486.01	2,486.01	2,486.01
9	**Other equity**						44,254.04
10	**Earnings per share (Face value of Rs. 2 each)**						
	Basic (in Rs. not annualised except for year ended 31 March 2026)	2.92	5.28	4.73	8.21	8.86	17.87
	Diluted (in Rs. not annualised except for year ended 31 March 2026)	2.92	5.28	4.72	8.19	8.85	17.85
	See accompanying notes to the unaudited financial results						

This space has been intentionally left blank

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

JEENA SIKHO LIFECARE LIMITED ZIRAKPUR

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91 - 01762-513185

STANDALONE STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

(Amount in Rs. lacs)

Particulars	Six months ended 30 September 2026 (Unaudited)	Six months ended 30 September 2025 (Unaudited)
Cash flows from operating activities		
Profit before tax	13,657.69	14,731.18
Adjustments to reconcile profit before tax to net cash flows :		
Depreciation and amortization expense	3,175.76	2,004.77
Finance costs	751.31	600.58
Share based payment expense	319.08	34.71
Allowance for expected credit loss	373.59	46.10
Gain on investments measured at fair value through profit and loss	(185.16)	(67.67)
Gain on sale of investment (net)	-	(8.69)
Gain on sale of property, plant and equipment (net)	(481.24)	(1.74)
Amounts written off	-	1.10
Deferred franchise deposit income on security deposits	3.98	-
Interest income	(507.79)	(61.95)
Interest income of security deposit	-	(63.90)
Operating profit before working capital changes and other adjustments	**17,107.22**	**17,214.49**
Working capital adjustments:		
Increase in inventories	(1,144.66)	(418.81)
Increase in trade receivables	(761.22)	(903.60)
Increase in financial assets	(1,541.33)	(43.12)
Increase in other assets	(1,796.55)	(1,106.71)
Increase in trade payables	815.09	718.62
(Decrease) / Increase in other financial liabilities	(71.06)	178.07
Increase in other liabilities	361.34	768.18
Increase in provisions	338.70	118.63
Cash generated from operating activities post working capital changes	**13,307.53**	**16,525.75**
Income tax paid	(4,532.64)	(2,779.40)
Net cash generated from operating activities (A)	**8,774.89**	**13,746.35**
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(1,365.49)	(2,303.76)
Proceeds from sale of property, plant and equipment	3,230.53	-
Payment of initial direct costs towards leases acquired	(61.13)	-
Payment towards exercise of share warrants (refer note 7)	(789.75)	-
Investments in equity instruments	-	(2.55)
Investments in mutual funds	(500.00)	(9,800.00)
Proceeds from sale of investments in mutual funds	-	1,003.69
Proceeds from recovery of loans (net)	-	75.00
Investments in bank deposits (net)	(2,364.27)	(6.79)
Interest received	460.89	27.58
Net cash used in investing activities (B)	**(1,389.22)**	**(11,006.83)**
C. Cash flows from financing activities		
Repayment of long-term borrowings	(12.52)	(12.52)
Repayment of short term borrowings	-	(1,002.40)
Payment of principal portion of lease liabilities	(1,385.03)	(1,617.16)
Payment of interest portion of lease liabilities	(748.14)	-
Interest paid	(1.57)	(2.96)
Net cash used in financing activities (C)	**(2,147.26)**	**(2,635.04)**
Net increase in cash and cash equivalents (A+B+C)	5,238.41	104.48
Cash and cash equivalents at the beginning of the year	1,515.62	2,297.87
Cash and cash equivalents at the end of the year	**6,754.03**	**2,402.35**

This space has been intentionally left blank

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

JEENA SIKHO LIFECARE LIMITED ZIRAKPUR

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91- 01762-513185

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

Consolidated Balance sheet as at: (Amount in Rs. lacs)

Particulars	30 September 2026 (Unaudited)	31 March 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	9,396.35	11,817.81
Right-of-use assets	14,901.64	11,404.12
Capital work-in-progress	141.82	206.15
Goodwill	5,811.82	5,811.82
Other intangible assets	191.27	260.15
Intangible assets under development	105.02	79.45
Financial assets		
(i) Investments	2,157.58	1,459.54
(ii) Other financial assets	1,288.38	1,173.81
Deferred tax asset (Net)	1,414.06	1,025.87
Other non-current assets	241.91	98.73
Total Non-current assets (A)	**35,649.85**	**33,337.45**
Current assets		
Inventories	3,170.54	2,021.82
Financial assets		
(i) Investments	10,289.11	9,512.24
(ii) Trade receivables	7,380.54	6,992.91
(iii) Cash and cash equivalents	6,877.08	1,637.30
(iv) Other bank balances	10,616.04	9,245.08
(v) Other financial assets	4,374.97	2,269.20
Other current assets	4,333.34	2,408.16
Total Current assets (B)	**47,041.62**	**34,086.71**
TOTAL ASSETS (A+B)	**82,691.47**	**67,424.16**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	2,486.01	2,486.01
Other equity	49,247.75	44,221.87
Non-controlling interest	(7.58)	(12.82)
Total Equity (C)	**51,726.18**	**46,695.06**
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Borrowings	20.08	26.50
(ii) Lease liabilities	13,109.06	9,548.25
(iii) Others financial liabilities	74.38	80.85
Provisions	602.04	562.52
Other non-current liabilities	6.92	12.49
Total Non-current liabilities (D)	**13,812.48**	**10,230.61**
Current liabilities		
Financial liabilities		
(i) Borrowings	12.82	18.92
(ii) Lease liabilities	3,678.88	3,136.09
(iii) Trade payables		
(a) Total outstanding dues of micro and small enterprises	827.65	769.49
(b) Total outstanding dues of creditors other than micro and small enterprises	2,149.98	1,545.16
(iv) Other financial liabilities	8,007.59	2,491.03
Other current liabilities	2,014.16	1,645.12
Provisions	324.05	77.63
Current tax liabilities (net)	137.68	815.05
Total Current liabilities (E)	**17,152.81**	**10,498.49**
Total liabilities (F=D+E)	**30,965.29**	**20,729.10**
TOTAL EQUITY AND LIABILITIES (C+F)	**82,691.47**	**67,424.16**

This space has been intentionally left blank

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

JEENA SIKHO LIFECARE LIMITED ZIRAKPUR

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91 - 01762-513185

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026

(Amount in Rs. lacs)

S. No.	Particulars	Quarter ended			Six months ended		Year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income**						
	a. Revenue from operations	23,512.91	22,440.48	18,984.51	45,953.39	36,413.10	80,136.39
	b. Other income	(193.52)	1,432.65	144.49	1,239.13	251.34	849.61
	Total Income	**23,319.39**	**23,873.13**	**19,129.00**	**47,192.52**	**36,664.44**	**80,986.00**
2	**Expenses**						
	a. Purchase of stock-in-trade and ayurvedic healthcare consumables	3,799.20	2,704.71	2,561.01	6,503.91	4,649.72	10,020.21
	b. Changes in inventories of stock-in-trade and ayurvedic healthcare consumables	(1,005.45)	(137.86)	(152.17)	(1,143.31)	(407.41)	(867.23)
	c. Employee benefits expense	4,826.74	4,417.79	3,316.87	9,244.53	6,313.02	14,840.48
	d. Finance costs	403.96	347.35	434.63	751.31	600.61	1,283.35
	e. Depreciation and amortization expense	1,649.15	1,538.89	1,039.70	3,188.04	2,004.86	4,769.20
	f. Other expenses	8,693.06	6,249.26	4,056.29	14,942.32	8,779.99	21,200.64
	Total Expenses	**18,366.66**	**15,120.14**	**11,256.33**	**33,486.80**	**21,940.79**	**51,246.65**
3	**Profit before tax (3-4)**	**4,952.73**	**8,752.99**	**7,872.67**	**13,705.72**	**14,723.65**	**29,739.35**
4	**Tax expense / (credit)**						
	a. Current tax	1,717.81	2,137.61	2,052.33	3,855.42	3,830.46	8,017.00
	b. Taxation for earlier years	-	-	-	-	-	14.10
	c. Deferred tax	(427.83)	26.37	(54.67)	(401.46)	(108.96)	(461.56)
	Total tax expense	**1,289.98**	**2,163.98**	**1,997.66**	**3,453.96**	**3,721.50**	**7,569.54**
5	**Profit for the quarter/ period/ year (5-6)**	**3,662.75**	**6,589.01**	**5,875.01**	**10,251.76**	**11,002.15**	**22,169.81**
6	**Other comprehensive income**						
	(i) Items that will not be reclassified to profit or loss						
	- Remeasurement gain/(loss) on defined benefit plans	(10.33)	63.09	9.19	52.76	68.21	79.01
	- Income tax related to items that will not be reclassified to profit or loss	2.59	(15.87)	(2.32)	(13.28)	(17.17)	(19.88)
	(ii) Item that may be reclassified to profit or loss						
	- Exchange differences on translation of foreign operations	(0.94)	-	-	(0.94)	-	0.32
7	**Total comprehensive income for the quarter/ period/ year (7+8)**	**3,654.07**	**6,636.23**	**5,881.88**	**10,290.30**	**11,053.19**	**22,229.26**
	Net Profit for the period attributable to:						
	Owners of the parent	3,667.26	6,594.54	5,876.76	10,261.79	11,003.90	22,185.08
	Non-controlling interests	(4.50)	(5.53)	(1.75)	(10.03)	(1.75)	(15.27)
	Other comprehensive income for the period attributable to:						
	Owners of the parent	(8.68)	47.22	6.87	38.54	51.04	59.45
	Non-controlling interests	-	-	-	-	-	-
	Total comprehensive income for the period attributable to:						
	Owners of the parent	3,658.58	6,641.76	5,883.63	10,300.33	11,054.94	22,244.53
	Non-controlling interests	(4.50)	(5.53)	(1.75)	(10.03)	(1.75)	(15.27)
8	**Paid-up equity share capital (Face value of Rs. 2 each)**	**2,486.01**	**2,486.01**	**2,486.01**	**2,486.01**	**2,486.01**	**2,486.01**
9	**Other equity**						44,221.87
10	**Earnings per share (Face value of Rs. 2 each)**						
	Basic (in Rs. not annualised except for year ended 31 March 2026)	2.95	5.30	4.73	8.25	8.85	17.84
	Diluted (in Rs. not annualised except for year ended 31 March 2026)	2.94	5.29	4.72	8.23	8.84	17.81
	See accompanying notes to the unaudited financial results						

This space has been intentionally left blank

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

JEENA SIKHO LIFECARE LIMITED ZIRAKPUR

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91 - 01762-513185

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

(Amount in Rs. lacs)

Particulars	Six months ended 30 September 2026 (Unaudited)	Six months ended 30 September 2025 (Unaudited)
Cash flows from operating activities		
Profit before tax	**13,705.72**	**14,723.65**
Adjustments to reconcile profit before tax to net cash flows :		
Depreciation and amortization expense	3,188.04	2,004.86
Finance costs	751.31	600.61
Share based payment expense	319.08	34.71
Allowance for expected credit loss	373.59	46.10
Gain on investments measured at fair value through profit and Loss	(185.16)	(67.67)
Gain on sale of investment (net) measured at fair value through profit and loss	-	(8.09)
Gain on sale of property, plant and equipment (net)	(481.24)	(1.74)
Amounts written off	-	1.10
Deferred franchise deposit income	3.98	-
Interest income of security deposits	-	(63.90)
Interest income on assets measured at amortised cost	(461.65)	(61.95)
Operating profit before working capital changes and other adjustments	**17,213.67**	**17,207.08**
Working capital adjustments:		
Increase in inventories	(1,148.72)	(422.22)
Increase in trade receivables	(761.22)	(903.60)
Increase in financial assets	(1,389.17)	(43.12)
Increase in other assets	(1,922.36)	(1,126.01)
Increase in trade payables	662.98	871.93
(Decrease) / Increase in other financial liabilities	(72.77)	178.07
Increase in other liabilities	361.87	768.18
Increase in provisions	338.70	118.63
Cash generated from operating activities post working capital changes	**13,282.98**	**16,648.94**
Income tax paid	(4,532.80)	(2,779.40)
Net cash generated from operating activities (A)	**8,750.18**	**13,869.54**
B. Cash flow from investing activities		
Purchase of property, plant and equipment	(1,365.85)	(2,446.56)
Proceeds from sale of property, plant and equipment	3,230.30	-
Payment of initial direct costs towards leases acquired	(61.13)	-
Payment towards exercise of share warrants (refer note 7)	(789.75)	-
Investments in mutual funds	(500.00)	(9,800.00)
Proceeds from sale of investments in mutual funds	-	1,003.69
Proceeds from recovery of loans (net)	-	100.00
Investments in bank deposits (net)	(2,364.27)	(6.79)
Interest received	473.72	27.58
Net cash used in investing activities (B)	**(1,376.98)**	**(11,122.08)**
C. Cash flow from financing activities		
Proceeds from issue of shares (non controlling interest)	-	2.45
Repayment of long-term borrowings	(12.52)	(12.52)
Repayment of short term borrowings (net)	-	(999.00)
Payment of principal portion of lease liabilities	(1,385.00)	(1,617.16)
Payment of interest portion of lease liabilities	(748.14)	-
Interest paid	(1.57)	(2.99)
Net cash used in financing activities (C)	**(2,147.23)**	**(2,630.12)**
Net increase in cash and cash equivalents (A+B+C)	5,225.97	117.34
Net foreign exchange difference	13.81	-
Cash and cash equivalents at the beginning of the year	1,037.30	2,297.87
Cash and cash equivalents at the end of the year	**6,877.08**	**2,415.21**

This space has been intentionally left blank

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

JEENA SIKHO LIFECARE LIMITED ZIRAKPUR

JEENA SIKHO LIFECARE LIMITED

Regd. Office : SCO 11, First Floor, Kalgidhar Enclave, Zirakpur, Mohali, Punjab 140604
CIN: L52601PB2017PLC046545

Website: www.jeenasikho.com Email: cs@jeenasikho.com Tel: 91 - 01762-513185

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2026

Segment-wise revenue and results for the quarter and six months ended 30 September 2026

(Amount in Rs. lacs)

Particulars	Quarter ended			Six months ended		Year ended
	30.09.2026	30.06.2026 *	30.09.2025 *	30.09.2026	30.09.2025 *	31.03.2026 *
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Segment Revenue						
Ayurvedic products/ medicines	14,388.63	11,828.31	9,592.27	26,216.94	17,594.78	41,569.28
Ayurvedic healthcare services	8,983.46	10,474.66	9,392.24	19,458.12	18,818.32	38,340.37
Others	140.82	137.51		278.33		226.74
Subtotal	**23,512.91**	**22,440.48**	**18,984.51**	**45,953.39**	**36,413.10**	**80,136.39**
Revenue from operations	**23,512.91**	**22,440.48**	**18,984.51**	**45,953.39**	**36,413.10**	**80,136.39**
Segment Results						
Ayurvedic products/ medicines	3,344.47	3,738.41	3,992.41	7,082.88	7,073.45	16,457.42
Ayurvedic healthcare services	2,990.67	4,656.83	4,598.22	7,647.50	8,823.22	15,636.07
Others	140.82	137.51		278.33		226.74
Subtotal	**6,475.96**	**8,532.75**	**8,590.63**	**15,008.71**	**15,896.67**	**32,320.23**
Unallocable expenses/ income:						
Less- Finance cost	(403.96)	(347.35)	(434.60)	(751.31)	(600.58)	(1,283.35)
Add- Other unallocable income	(277.36)	1,401.51	144.49	1,124.15	251.34	849.61
Less- Other unallocable expenses #	(841.91)	(833.92)	(427.85)	(1,675.83)	(823.78)	(2,147.14)
Profit before tax	**4,952.73**	**8,752.99**	**7,872.67**	**13,705.72**	**14,723.65**	**29,739.35**

For internal reporting purposes, the Company's Chief Operating Decision Maker ("CODM") allocates unallocable expenses as presented above in the proportion of respective segment revenue.

* During the quarter and period ended 30 September 2026, the CODM revised the basis of allocation of advertisement expenditure to make it more specific and to provide more relevant information on segment performance. Accordingly, the comparative figures have been regrouped/reclassified to ensure comparability.

This space has been intentionally left blank

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

JEENA SIKHO LIFECARE LIMITED ZIRAKPUR

Notes to standalone and consolidated financial results:

1 The statutory auditors have reviewed the standalone financial results of Jeena Sikho Lifecare Limited ("the Holding Company") and consolidated financial results, comprising of the Holding Company and its subsidiaries namely Jeena Green Resources Private Limited and Jeena Sikho International LLC (together referred to as "the Group") for the quarter and six months period ended 30 September 2026. In terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, these standalone and consolidated financial results ("financial results") for the quarter and six months period ended 30 september 2026 were reviewed by the Audit Committee at its meeting held on 14 November 2026 and approved by the Board of Directors at their meeting held on 14 November 2026.

2 The above standalone and consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.

3 As per Ind AS 108 operating segment is a component of the Group that engages in business activities whose operating results are regularly reviewed by the Group's Chief Operating Decision Maker ('CODM)' to make decisions about resources to be allocated to the segment and assess its performance; and for which discrete financial information is available. Accordingly, The Group has identified the following operating segments:

a) Ayurvedic Products and Medicines
b) Ayurvedic Healthcare Services
c) Others- significantly comprising royalty income, revenue share of income from diagnostic services,

The CODM does not review assets and liabilities for each operating segment separately, hence segment information relating to the total assets and liabilities has not been furnished.

In accordance with Ind AS 108 "Operating Segments", the Company has opted to present segment information along with the consolidated financial results of the Group.

4 The Holding Company sold land and building constituting its Derabassi hospital facility during the quarter and period ended 30 September 2026 and took back the premises on lease to ensure continued operations the hospital.

5 Subsequent to the quarter and six months period ended 30 September 2026, the Holding Company incorporated Ayugenomics Private Limited as a subsidiary on November 11, 2026. The Company has subscribed to 30,000 equity shares of ₹10 each, aggregating to Rs. 3.00 lacs, representing 60% of the equity share capital of the said subsidiary. Ayugenomics Private Limited has been incorporated, inter alia, to undertake research, development, testing, diagnostic and clinical services integrating genomics and allied omics sciences with Ayurveda.

6 Subsequent to the quarter and six months period ended 30 September 2026, the Nomination and Remuneration Committee of the Holding Company, vide resolution dated October 10, 2026, approved the allotment of 23,374 equity shares of face value of ₹2 each to eligible employees pursuant to the exercise of options under the Jeena Sikho Lifecare Limited Employee Stock Option Scheme 2024 ("ESOS 2024"). Consequent to the said allotment, the paid-up equity share capital of the Company increased from ₹24,86,01,460, comprising 12,43,00,730 equity shares of ₹2 each, to ₹24,86,48,208, comprising 12,43,24,104 equity shares of ₹2 each. The equity shares so allotted rank pari passu in all respects with the existing equity shares of the Company.

7 During the quarter and six months period ended 30 September 2026, Jeena Sikho Lifecare Limited exercised its conversion rights in respect of 4.5 lacs convertible warrants allotted by Chandan Healthcare Limited and remitted the balance 75% consideration amounting to ₹789.75 lacs towards conversion into 4.5 lacs fully paid-up equity shares. The allotment of the aforesaid equity shares is pending approval from the stock exchange.

8 The shareholders at the Annual General Meeting held on 28 September 2026 approved a final dividend of Rs. 4.50 per equity share which was recommended by the Board of Directors of the Holding Company, at its meeting held on 30 May 2026.

Place: Zirakpur, Punjab
Date: 14 November 2026

For Jeena Sikho Lifecare Limited

For JEENA SIKHO LIFECARE LIMITED
Manish Grover Managing Director

Manish Grover
Managing Director
DIN - 07557886

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

JEENA SIKHO LIFECARE LIMITED ZIRAKPUR